《大行》瑞银首予三生制药(01530.HK)“买入”评级 目标价30元 重大许可协议印证研发能力

阿斯达克财经
Jun 27, 2025

瑞银发表报告,首次覆盖三生制药(01530.HK) ,给予“买入”评级,目标价30元。报告指,三生制药核心产品针对血液学和自身免疫疾病,认为,近期与辉瑞(PFE.US)  就SSGJ-707(PD-1/VEGF双特异性抗体)达成的总额创纪录61.5亿美元的许可协议,体现了对三生强大研发能力的认可。该行看好SSGJ-707海外高峰销售额及其他管线资产价值的上升潜力,预测三生制药在2024至2034...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10